academic article

• Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia..  Cancer Sciecne.  110:1931-1946. 2019
• Drugging DNA repair to target T-ALL cells..  Leukemia & lymphoma.  59:1746-1749. 2018
• High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. 2017
• Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults..  Blood.  129:572-581. 2017
• Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. 2016
• Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia..  Nature communications.  7:-. 2016
• Characterization of leukemias with ETV6-ABL1 fusion..  Haematologica.  101:1082-1093. 2016
• MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: A children's oncology group study..  Leukemia.  :-. 2016
• Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia..  Cancer cell.  29:186-200. 2016
• Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia..  Molecular cancer therapeutics.  14:364-374. 2015
• A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. 2015
• Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia..  Nature communications.  6:-. 2015
• Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. 2014
• Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project..  Blood.  121:485-488. 2013
• Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia..  Blood.  120:833-842. 2012
• Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia..  Cancer cell.  22:153-166. 2012
• Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study..  Blood.  119:3512-3522. 2012
• Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia..  Blood.  120:3510-3518. 2012
• The genetic basis of early T-cell precursor acute lymphoblastic leukaemia..  Nature.  481:157-163. 2012
• Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group..  Blood.  118:3080-3087. 2011
• Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  28:3816-3823. 2010
• Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia..  Blood.  115:1394-1405. 2010
• Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome..  Blood.  116:4874-4884. 2010
• Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia..  Blood.  115:5312-5321. 2010
• Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia..  The New England journal of medicine.  360:470-480. 2009
• JAK mutations in high-risk childhood acute lymphoblastic leukemia..  Proceedings of the National Academy of Sciences of the United States of America.  106:9414-9418. 2009
• Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia..  Nature genetics.  41:1243-1246. 2009